Clinical Report: Influence of SGLT2 Inhibitors on AF Recurrence Post-Ablation

Overview

This study investigates the impact of SGLT2 inhibitors on atrial fibrillation (AF) recurrence and cardiac function in heart failure (HF) patients post-catheter ablation. Results indicate that SGLT2 inhibitors significantly reduce AF recurrence rates and improve cardiac function compared to non-SGLT2 inhibitor treatments.

Background

Atrial fibrillation is a common arrhythmia that can exacerbate heart failure, leading to poor outcomes. The recurrence of AF after catheter ablation is notably high in patients with HF, necessitating effective post-ablation management strategies. SGLT2 inhibitors have emerged as a promising treatment option, showing potential benefits in reducing AF recurrence and improving cardiac function.

Data Highlights

Key Findings

• SGLT2i group had a significantly lower AF recurrence rate (13.25%) compared to the non-SGLT2i group (25.88%, P = 0.039).
• Severe atrial fibrosis and SGLT2i administration were identified as independent predictors of AF recurrence.
• At 12-month follow-up, SGLT2i treatment was associated with a reduced left atrial diameter and improved left ventricular ejection fraction.
• Meta-analysis of 13 studies indicated SGLT2i reduced the likelihood of AF recurrence (RR = 0.59, P < 0.001).
• SGLT2i use was linked to decreased risks of all-cause mortality (RR: 0.66, P = 0.011).

Clinical Implications

The findings suggest that SGLT2 inhibitors should be considered in the management of AF patients with heart failure, particularly post-catheter ablation, to reduce recurrence rates and improve cardiac function. Clinicians should evaluate the incorporation of SGLT2 inhibitors into treatment plans for these patients.

Conclusion

SGLT2 inhibitors demonstrate a beneficial role in reducing AF recurrence and enhancing cardiac function in patients with heart failure following catheter ablation. Their use may contribute to improved long-term outcomes in this patient population.

References

1. Drugs - Real World Outcomes, 2021 -- Association of Sodium-Glucose Cotransporter-2 Inhibitors with Decreased Heart Failure Hospitalization Risk
2. Clinical Research in Cardiology, 2021 -- Impact of Receptor Specificity on the Advantages of SGLT2 Inhibitors
3. Basic Research in Cardiology, 2024 -- Exploring the Impact of Dapagliflozin on Atrial Fibrillation
4. Clinical Research in Cardiology, 2026 -- Characteristics and outcomes of patients with heart failure
5. 2023 Guideline for Diagnosis and Management of Atrial Fibrillation, American College of Cardiology
6. SGLT2 inhibitors and risk of atrial fibrillation recurrence after catheter ablation: A systematic review and meta-analysis
7. 2023 ACC Guideline for AF
8. SGLT2 Inhibitors and AF Recurrence
9. Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - American College of Cardiology